Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-β in human retinal glial cells

Investigative Ophthalmology and Visual Science

Volumn 43, Issue 8, 2002, Pages 2799-2805

  Schacke, Wolfgang ^a   Beck, Karl Friedrich ^a   Pfeilschifter, Josef ^a   Koch, Frank ^a   Hattenbach, Lars Olof ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLIA CELL; HUMAN; HUMAN CELL; MORPHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RETINA CELL; WOUND HEALING;

BLOTTING, WESTERN; CELLS, CULTURED; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEUROGLIA; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; SMAD2 PROTEIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036327303     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
2. Plasminogen activators, tissue degradation and cancer
3. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis
4. Immunolocalization of tissue plasminogen activator in the diabetic and non-diabetic retina and choroid
5. Vitreous concentrations of tissue plasminogen activator and tissue plasminogen activator inhibitor are associated with vascular endothelial growth factor in proliferative diabetic vitreoretinopathy
6. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes
7. Plasminogen in proliferative vitreoretinal disorders
8. Regulation of plasminogen activation by TGF-β in cultured human retinal endothelial cells
9. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin
10. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
11. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia
12. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity
13. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: Evidence for atrophic paracrine relation
14. Expression of transforming growth factor-betas and their receptors by human retinal glial cells
15. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy
16. Vessel formation by choroidal endothelial cells in vitro is modulated by retinal pigment epithelial cells
17. Role of transforming growth factor-β in human disease
18. The role for transforming growth factor-beta in human cancer
19. Transforming growth factor-beta: Vasculogenesis, angiogenesis and vessel wall integrity
20. Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization
21. 2 in the vitreous in proliferative diabetic retinopathy
22. Expression of vitreous cytokines in proliferative vitreoretinopathy: A prospective study
23. Intravitreal growth factors in proliferative retinopathy: Correlation with neovascular activity and glycaemic management
24. TGF-beta receptor mediated signalling through Smad2, Smad3 and Smad4
25. Transcriptional control by the TGF-β/Smad-signaling system
26. Cytomegalovirus infection decreases expression of thrombospondin-1 and-2 in cultured human retinal glial cells: Effects of antiviral agents
27. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
28. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
29. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis
30. Tissue plasminogen activator activity in human aqueous humor
31. Distribution of tissue plasminogen activator in human and monkey eyes: An immunohistochemical study
32. Localization of urokinase-type plasminogen activator in human eyes: An immunocytochemical study
33. Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells
34. Insulin-like growth factor I stimulates proliferation, migration and plasminogen activator release by human retinal pigment epithelial cells
35. Immunocytochemical identification of Miillers' glia as a component of human epiretinal membranes
36. Characterization of glial involvement in proliferative diabetic retinopathy
37. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta
38. Defective hematopoiesis and vasculogenesis in transforming growth factor-β knock out mice
39. The response of endothelial cells to TGF β-1 is dependent upon cell shape, proliferative state and the nature of the substratum
40. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation
41. Upregulation of transforming growth factor-β after panretinal photocoagulation
42. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway